Form 8-K - Current report:
SEC Accession No. 0001699031-25-000016
Filing Date
2025-02-20
Accepted
2025-02-20 16:05:07
Documents
15
Period of Report
2025-02-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gral-20250220.htm   iXBRL 8-K 30097
2 EX-99.1 ex9912024q4earningspressre.htm EX-99.1 177135
6 grail_logoxvelvet.jpg GRAPHIC 25011
  Complete submission text file 0001699031-25-000016.txt   387409

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gral-20250220.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gral-20250220_lab.xml EX-101.LAB 22530
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gral-20250220_pre.xml EX-101.PRE 13045
17 EXTRACTED XBRL INSTANCE DOCUMENT gral-20250220_htm.xml XML 3216
Mailing Address 1525 O'BRIEN DRIVE MENLO PARK CA 94025
Business Address 1525 O'BRIEN DRIVE MENLO PARK CA 94025 (833) 694-2553
GRAIL, Inc. (Filer) CIK: 0001699031 (see all company filings)

EIN.: 863673636 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42045 | Film No.: 25645229
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)